Introduction {#sec1}
============

Cervical cancer is the most prevalent reproductive malignancy, with an estimated 569847 new cases and 311365 deaths worldwide in 2018. Although its prognosis has been improved by the combination of screening and surgery, the disease still brings the fourth highest morbidity and mortality among females worldwide \[[@B4]\].

Human papillomavirus (HPV) is one player in cervical cancer, however, not all the infected patients develop the cancer ultimately, indicating that HPV infection is a necessary but not sufficient pathogenic condition \[[@B42]\]. Additionally, genetic and epigenetic alternations may also be involved \[[@B30],[@B40]\].

Epigenetics focuses on heritable change in gene expression not mediated by changes within DNA sequence \[[@B3]\]. Altered methylation in DNA bases, either hypomethylation or hypermethylation, is a key event in carcinogenesis \[[@B17]\]. As cervical cancer progresses, epigenetic alteration rises to a level high enough to change gene expression. Epigenetic regulatory mechanisms in cervical cancer include DNA methylation, the hottest topic in this area, and post-translational modifications of histone proteins \[[@B10]\].

Based on high-throughput platforms, microarrays have emerged to screen genetic or epigenetic alternations in cancers in recent years \[[@B20]\]. Some differentially expressed genes (DEGs) in cervical intraepithelial neoplasia have been identified with this tool \[[@B46]\]. In addition, to explore differentially methylated genes (DMGs), aberrant methylation analysis has been applied \[[@B43]\]. However, these studies did not carry out a conjoint analysis that may result in insufficient power to discover key genes and pathways related to multiple cellular process and biological function. Differentially expressed and methylated genes can be detected using gene expression and methylation microarray data.

In our study, data from gene expression microarrays (GSE9750), gene methylation microarrays (GSE46306), as well as the expression profiles of oncogenes and tumor suppressor genes (TSGs) were integrated and analyzed by a series of bioinformatics tools. We used R software to obtain DEGs and DMGs and Venn diagram to overlap three datasets. Analyses also included gene-enrichment analysis (GO) and pathways (KEGG), protein--protein interaction (PPI) network analysis, and the identification and validation of oncogenes and TSGs. In our study, we aimed to screen out the aberrantly methylated and differentially expressed genes and associated pathways in cervical carcinogenesis. Some oncogenes or TSGs might be applied as biomarkers or therapeutic targets for cervical cancer.

Methods {#sec2}
=======

Microarray data profile {#sec2-1}
-----------------------

We searched the gene expression profile dataset (GSE9750) and methylation profile dataset (GSE46306) on Gene Expression Omnibus (GEO) database (<https://www.ncbi.nlm.nih.gov/geo/>). Based on the GPL570 platform \[HG-U133_Plus_2\] Affymetrix Human Genome U133 Plus 2.0 Array \[[@B12]\], data from GSE9750 covered 33 samples of cervical cancer and 24 normal cervix samples. Based on the GPL13534 ((Illumina HumanMethylation450 BeadChip (HumanMethylation450_15017482)) \[[@B38]\], the methylation-profile microarray data from GSE46306 covered 6 cervical cancer samples and 20 normal samples.

Identification of DEGs and DMGs {#sec2-2}
-------------------------------

To explore the DEGs and DMGs, we selected the 'limma' packages \[[@B29]\] to process in GSE9750 and GSE46306 datasets. For DEGs, cut-off criteria were set as \|logFC\| \> 1, and the adj.*p*-value \< 0.05. For DMGs, cut-off criteria were set as FDR \< 0.05 and \|logFC\| \> 0.2. Subsequently, oncogene and TSG lists were produced from two online databases (<http://ongene.bioinfo-minzhao.org/>; <https://bioinfo.uth.edu/TSGene/index.html>) respectively. Furthermore, we employed an online Venn diagram \[[@B7]\] (<http://bioinfogp.cnb.csic.es/tools/venny/>) to identify the intersection of nodes among DEGs, DMGs, oncogenes, and TSGs. As a result, up-regulated hypomethylated oncogenes as well as down-regulated hypermethylated TSGs were retrieved.

PPI network construction {#sec2-3}
------------------------

Based on the aforementioned oncogenes and TSGs, we built a PPI network with the Search Tool for the Retrieval of Interacting Genes (STRING) database \[[@B35]\] (<https://string-db.org/cgi/input.pl>).

Pathway analysis of aberrantly methylated DEGs {#sec2-4}
----------------------------------------------

Gene ontology (GO) function and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were conducted for our selected genes with an online tool FunRich \[[@B26]\] (<http://www.funrich.org/>). *P*\<0.05 was considered as statistically significant.

Validation of the selected genes {#sec2-5}
--------------------------------

To further validate the expression profiles of oncogenes and TSGs, online software Gene Expression Profiling Interactive Analysis (GEPIA) \[[@B36]\] (<http://gepia.cancer-pku.cn/>) was used. For validation of the aberrantly methylated differentiated expressed genes, Illumina Human Methylation 450 platform in Cancer Genome Atlas (TCGA) database was assessed. To validate the selected oncogenes/TSGs on the translational level, immunohistochemistry staining results of both normal and cancerous cervical samples were assessed using the Human Protein Atlas database (<https://www.proteinatlas.org/>). ROC curve analysis was conducted to distinguish the normal from the cancerous tissues. We used cBioPortal tool (cBio Cancer Genomics Portal, <http://www.cbioportal.org/>) to find out genetic alterations in the hub genes and correlation between messenger RNA (mRNA) expression and DNA methylation in cervical cancer.

Gene Set Enrichment Analysis {#sec2-6}
----------------------------

In TCGA, 306 cervical cancer samples were divided into two groups in the light of the median expression level. In order to identify the five hub genes' underlying functions and the enrichment of biological processes (BPs) in the ranked DEGs between the two groups, Gene Set Enrichment Analysis (GSEA) (<http://software.broadinstitute.org/gsea/index.jsp>) was performed \[[@B33]\]. Collection of annotated gene set of c2.cp.kegg.v6.0.symbols.gmt in Molecular Signatures Database (MSigDB, <http://software.broadinstitute.org/gsea/msigdb/index.jsp>) was selected as the reference gene sets. Additionally, we used 'Clusterprofiler' package in R to handle the datasets, and 'Enrichplot' package to tease out the enriched pathways of the crucial genes. The adj.*p*\<0.05 was set as the cut-off criterion.

Results {#sec3}
=======

DEGs and DMGs in cervical cancer {#sec3-1}
--------------------------------

The expression matrices from GSE9750 contained 33 cervical cancer samples and 24 normal samples. The DEGs were shown with a volcano plot and a clustering heat map ([Figure 1](#F1){ref-type="fig"}A,B). We obtained 1313 DEGs, including 690 up-regulated genes and 623 down-regulated genes. A total of 1405 DMGs were obtained in GSE46306, as shown in the heat map ([Figure 1](#F1){ref-type="fig"}C). As a result, 481 hypomethylated and 924 hypermethylated genes were also obtained.

![The results of DEGs in GSE9750, and DMGs in GSE46306\
(**A**) Volcano Plot visualizing all the DEGs. Red dots represent up-regulated genes, green dots represent down-regulated genes, and black dots represent genes without differential expression. (**B**) Heat-map hierarchical clustering revealed the top 200 genes that were differentially expressed in cervical cancer (CC) groups when compared with control groups. Red and green colors indicate higher expression and lower expression, respectively. (**C**) Heat map of the DMPs. Hierarchical clustering showed separate groupings of DMPs for CC tissue and normal tissue.](bsr-40-bsr20194365-g1){#F1}

Aberrantly methylated DEGs {#sec3-2}
--------------------------

We got 32 hypomethylated and highly expressed genes (Hypo-HGs) and 44 Hyper-LGs. To pinpoint the aberrantly methylated DEGs, Hypo-HGs were overlapped with oncogenes, and Hyper-LGs with TSGs. Correspondingly, we identified two up-regulated hypomethylated oncogenes ([Figure 2](#F2){ref-type="fig"}A), which may trigger tumorigenesis potentially by up-regulating gene expression after hypomethylation. Meanwhile, we retrieved eight down-regulated hypermethylated TSG ([Figure 2](#F2){ref-type="fig"}B), indicating aberrant hypermethylation may trigger tumorigenesis through lowering the expression of these genes.

![Aberrantly methylated and differentially expressed oncogenes and TSGs\
(**A**) Thirty-two hypomethylated and up-regulated genes were identified, including two oncogenes. (**B**) Forty-four hypermethylated and down-regulated genes were identified, including eight TSGs.](bsr-40-bsr20194365-g2){#F2}

PPI network construction {#sec3-3}
------------------------

STRING online database was employed to construct PPI networks. Based on the Hypo-HGs, a PPI network containing 31 nodes and 60 edges was constructed, with a PPI enrichment *P*-value of 5.77e-09 (Supplementary Figure S1A). Based on the Hyper-LGs, a PPI network containing 44 nodes and 69 edges was constructed, with a PPI enrichment *P*-value of 1.79e-07 (Supplementary Figure S1B). Those genes were used for further functional analyses.

Pathway analysis of aberrantly methylated DEGs {#sec3-4}
----------------------------------------------

There were biological process (BP), cellular component (CC), and molecular function (MF) in enriched GO terms. GO analysis showed that pyroptosis, positive regulation of interleukin-1 and positive regulation of nuclease activity for BP production were significantly enriched in Hypo-HGs ([Figure 3](#F3){ref-type="fig"}A). For CC analysis, AIM2 inflammasome complex, microtubule plus-end and NLRP3 inflammasome complex were significantly enriched in Hypo-HGs ([Figure 3](#F3){ref-type="fig"}B). For MF analysis, Hypo-HGs were significantly enriched in solute proton symporter activity, DNA insertion or deletion binding and phosphorylase activity ([Figure 3](#F3){ref-type="fig"}C). KEGG analysis indicated that up-hypomethylated genes mainly contributed to cell cycle, senescence, and autophagy in cancer ([Figure 3](#F3){ref-type="fig"}D).

![GO functional annotation and KEGG analysis of DEGs and DMGs\
(**A**) The top ten enriched BPs of Hypo-HGs (hypomethylated, highly expressed genes). (**B**) The top ten enriched CCs of Hypo-HGs. (**C**) The top ten enriched MFs of Hypo-HGs. (**D**) The top ten enriched KEGG pathways of Hypo-HGs. (**E**) The top ten enriched BPs of Hyper-LGs (hypermethylated, lowly expressed genes). (**F**) The top ten enriched CCs of Hyper-LGs. (**G**) The top ten enriched MFs of Hyper-LGs. (**H**) The top ten enriched KEGG pathways of Hyper-LGs.](bsr-40-bsr20194365-g3){#F3}

In comparison, Hyper-LGs were mainly associated with (i) vascular smooth muscle contraction, negative regulation of blood vessel diameter, and regulation of gene expression (BP analysis, [Figure 3](#F3){ref-type="fig"}E); (ii) axolemma, juxtaparanode region of axon, and paranode region of axon (CC analysis, [Figure 3](#F3){ref-type="fig"}F); (iii) acly-CoA oxidase activity, BMP receptor activity, and fatty acid transporter activity (MF analysis, [Figure 3](#F3){ref-type="fig"}G). These genes were mainly enriched in estrogen receptor pathway, estrogen signaling pathway and regulation of Wnt/β-catenin signaling by small molecules (KEGG analysis, [Figure 3](#F3){ref-type="fig"}H).

Validation of the selected genes {#sec3-5}
--------------------------------

We employed data from GEPIA to validate the role of the differentially expressed and methylated genes in carcinogenesis. Two upregulated-hypomethylated oncogenes, along with eight downregulated-hypermethylated TSGs, showed differential expression between normal tissues and cancer tissues ([Figure 4](#F4){ref-type="fig"}). In addition, based on TCGA CESC data, we identified five DMGs: *ESR1, EPB41L3, EDNRB, ID4*, and *PLAC8* ([Figure 5](#F5){ref-type="fig"}). Additionally, the immunohistochemistry staining images from Human Protein Atlas database indicated the up-regulation of *PLAC8* gene and the down-regulation of *ESR1* and *EDNRB* genes. Besides, the expression of *EPB41L3* showed no significant difference between normal tissues and tumor tissues, and immunohistochemistry staining of *ID4* was not obtained in Human Protein Atlas database ([Figure 6](#F6){ref-type="fig"}). Moreover, *ESR1, EPB41L3*, and *ID4* all showed an AUC of more than 0.7 and the combined diagnostic power of the five genes was 0.987 ([Figure 7](#F7){ref-type="fig"}A), which were enough to distinguish cervical cancer tissues from the normal tissues.

![Validation of the ten genes in the GEPIA\
Box plots showing the ten genes in mRNA expression, using data from the TCGA database in GEPIA. The statuses of the expression of nine genes were the same as in our study. \*：*P*-values\<0.05. (*ADAM28* was not statistically significant).](bsr-40-bsr20194365-g4){#F4}

![Validation of the ten genes in the TCGA database\
Violin plots showing the methylation status of the five genes was in accordance with the data from the TCGA database.](bsr-40-bsr20194365-g5){#F5}

![Immunohistochemistry of the four genes based on The Human Protein Atlas\
(**A**) Protein levels of PLAC8 in cancer tissues (staining: high; intensity: strong; quantity: \>75%). Protein levels of PLAC8 in the normal tissues (staining: negative; intensity: negative; quantity: none). (**B**) Protein levels of ENDRB in cancer tissues (staining: negative; intensity: negative; quantity: none). Protein levels of ENDRB in the normal tissues (staining: low; intensity: weak; quantity: \>75%). (**C**) Protein levels of ESR1 in cancer tissues (staining: low; intensity: moderate; quantity: \<25%). Protein levels of ESR1 in the normal tissues (staining: high; intensity: strong; quantity: 75-25%). (**D**) Protein levels of EPB41L3 in the tumor tissues (staining: negative; intensity: negative; quantity: none). Protein levels of EPB41L3 in the normal tissues (staining: negative; intensity: negative; quantity: none).](bsr-40-bsr20194365-g6){#F6}

![ROC curve analysis, suvival analysis and function analysis of the hub genes\
(**A**) ROC curve analysis was implemented to evaluate the capacity of five genes to distinguish the cervical cancer from the normal tissues. (**B**) The prognostic significance of hub genes in cervical cancer (CSCC). Lower levels of *ESR1* and *EPB41L3* were associated with poorer overall survival time, respectively. (**C,D**) GSEA using TCGA CESC databases. The ten most functional gene sets enriched in CESC samples.](bsr-40-bsr20194365-g7){#F7}

Furthermore, Human Protein Atlas database was applied to gain survival time and gene expression levels, to assess the prognostic significance of the five aberrantly methylated and differentially expressed genes. Kaplan--Meier method was used to evaluate survival time data of each identified gene. Analysis demonstrated lower expression levels of *ESR1* and *EPB41L3* were correlated with shorter survival time ([Figure 7](#F7){ref-type="fig"}B).

GSEA {#sec3-6}
----

To explore the functions of five genes in cervical cancer, we conducted GSEA to search pathways enriched in the TCGA samples. Ten enriched pathways in the gene sets (*n*=306) included cell adhesion molecules (CAMs), Wnt signaling pathway, axon guidance, calcium signaling pathway, neuroactive ligand receptor interaction, arrhythmogenic right ventricular cardiomyopathy ARVC, hypertrophic cardiomyopathy HCM, vascular smooth muscle contraction, dilated cardiomyopathy, and ECM receptor interaction (adj.*P*\<0.05) ([Figure 7](#F7){ref-type="fig"}C,D).

Genetic information of the five genes {#sec3-7}
-------------------------------------

The genetic alteration in the five genes was analyzed with cBioPortal software. The network constructed by *ESR1* and *EDNRB* and their 50 most associated neighbor genes were exhibited (only two of the five genes had a joint node, while the remaining three genes had no junctions and were not shown). In addition, drugs targeting the five genes were shown, only *ESR1* and *EDNRB* were taken for drug targets currently ([Figure 8](#F8){ref-type="fig"}A). [Figure 8](#F8){ref-type="fig"}B,C illustrated that the five genes were changed in 82 (27%) of the 308 cases/patients (310 in total); *EDNRB, EPB41L3*, and *ID4* showed most diverse alterations, including amplification, missense mutation etc. The relevance between mRNA and DNA methylation of the five genes in the TCGA CESC patients was demonstrated in [Figure 8](#F8){ref-type="fig"}D. We found that methylation negatively regulated the mRNA expression of the five genes.

![Genetic alterations in the five genes\
(**A**) The network contained 52 nodes, including two query genes and 50 most interactive neighbor genes. The relationship between hub genes and drugs. (**B**) A visual summary across a set of CESC (data from cervical squamous cell carcinoma TCGA, provisional) showed the genetic alteration of the seven genes appeared in 82 (27%) of the 308 sequenced cases/patients (310 total). (**C**) An overview of changes in the five genes in the genomics datasets of TCGA. (**D**) Correlation between mRNA and DNA methylation in the five genes in TCGA CESC patients.](bsr-40-bsr20194365-g8){#F8}

Dicussion {#sec4}
=========

The development of cervical cancer was a complicated process. Elucidating the underlying molecular mechanisms of oncogenesis would extremely benefit the diagnosis, treatment and prognosis evaluation of cervical cancer. Database-based bioinformatics analysis is increasingly adopted to screen out targeted biological molecules that might have a guiding role in the diagnosis and treatment of tumors \[[@B20]\].

In the present study, we utilized NCBI-GEO to analyze the data of gene expression (GSE9750) and gene methylation (GSE46306) microarrays for cervical cancer. We used the R software to screen genes which were differentially expressed.

In our research, we identified two up-regulated hypomethylated oncogenes and eight down-regulated hypermethylated TSGs in cervical cancer. To predict the protein interaction among these genes, PPI network was constructed using the online STRING database. Furthermore, based on TCGA CESC data, we obtained five DMGs. Functional and enrichment analyses demonstrated the pathways and hub genes regulated by aberrant methylation. Meanwhile, the Kaplan--Meier analysis illustrated that lower levels of *EPB41L3* and *ESR1* were relevant to shorter survival time of CESC patients.

As was implied by FunRich analysis, Hypo-HGs were significantly associated with cell cycle and autophagy. Increasing evidence indicates that aberrant cell cycle plays a crucial role in the development of cancer \[[@B45]\], due to the dysregulation of TSGs or oncogenes, such as *p53, p16*, and cyclin D1, etc. \[[@B31]\]. Cyclin D1 is essential for cell cycle G~1~ \[[@B2]\]. Cyclin D1 aberrantly expressed is implicated in the progression of cervical cancer \[[@B1]\]. Cell cycle could participate significantly in the tumorigenesis of cervical cancer due to cell cycle regulators. Studies have explored the dual effects of autophagy in cancer. How autophagy functions in tumor suppression has been explained, like cell death, senescence, and metabolic stress \[[@B18]\]. Autophagy facilitates neoplasm growth by supporting cellular metabolism. Inhibiting autophagy has become a rationale in cancer therapy development \[[@B19]\].

For Hyper-LGs in cervical cancer, estrogen receptor pathway and Wnt/β-catenin signaling pathway were enriched. Multi-parity and oral contraceptives usages, particular long-term usage, are powerful risks of cervical cancer in HPV-infected women, raising the potential that estrogen and HPV infection might exert synergistic effect to cervical cancer development \[[@B28]\]. Previous studies have discovered that loss of exogenous estrogen, cervical disease progressed slowly and pre-existing neoplasia regressed partially in HPV transgenic mice. In addition, treated with estrogen, ERα-deficient HPV transgenic mice did not show faster development of cervical cancer \[[@B8]\]. Therefore, estrogen and ERα might play a key part in the tumorigenesis of cervical cancer. The Wnt/β-catenin signaling pathway, through activating β-catenin to initiate its downstream target genes transcription, could promote tumorigenesis, invasion, and metastasis \[[@B44]\]. Previous study found that deprivation of Wnt2 inhibited SiHa cell migration and invasion, as well as reversed EMT by restraining theWnt2/β-catenin pathway. Moreover, overexpression of Wnt2 led to metastasis in cervical cancer, which was associated with activation of β-catenin and induction of EMT \[[@B48]\]. In conclusion, Wnt/β-catenin signaling pathway aberrantly activated could enhance cervical cancer metastasis and invasion.

GEPIA was employed to validate the role of the ten selected genes in carcinogenesis. Two up-regulated hypomethylated oncogenes and eight down-regulated hypermethylated TSGs showed expression difference between cancer samples and normal samples. We next accessed TCGA CESC data to validate the performance of five DMGs, including *ESR1, EPB41L3, EDNRB, ID4*, and *PLAC8*. The results of boxplots based on TCGA database were mostly consistent with the data of GEO analysis. We further used immunohistochemistry staining to verify the deregulation of the gene expression. Last, we performed ROC curve analysis to assess the capacity of five genes to distinguish cervical cancer from the normal tissues.

These five hub genes are involved in tumor progression. *PLAC8* is a cysteine-rich protein highly expressed in giant trophoblasts and spongiotrophoblast layer in placenta \[[@B11]\]. In a recent study, *PLAC8* could facilitate the EMT in nasopharyngeal carcinoma \[[@B15]\]. In addition, high expression of *PLAC8* in clear cell renal carcinoma was correlated to malignant progression and poor prognosis. \[[@B32]\]. In our study, we found that the expression of *PLAC8* was increased by hypomethylation, demonstrating that *PLAC8* may function as an initiator of cervical cancer proliferation.

*EPB41L3* is a TSG which facilitates tumor cell apoptosis and inhibits its proliferation \[[@B21]\]. Overexpressed of *EPB41L3* could enhance the migration and invasion of multiple cancers, such as esophageal cancer \[[@B47]\], lung cancer \[[@B22]\], and hepatocellular carcinoma \[[@B49]\]. Methylation of *EPB41L3* was lower than or equal to that in CIN1 group, but rose significantly till to the peak in CIN2/3 group \[[@B41]\]. Our study showed that lower expression levels of *EPB41L3* was related to shorter survival time. As a tumor suppressor, *ID4* could promote the proliferation and inhibit the apoptosis of tumor cells in prostate \[[@B23]\], lung \[[@B5]\], and gastric \[[@B6]\] cancers. Expression of *ID4* is lowered by its promoter hypermethylation \[[@B25]\]. In the present study, *EPB41L3* and *ID4* had a possibility of 7% mutation in cervical cancer, so we speculated that the mutation led to the aberrant methylation or deregulation of both genes. Furthermore, hypermethylation of *EPB41L3* and *ID4* may suppress the development of cervical cancer.

*ESR1*, a nuclear hormone receptor and oncoprotein, is expressed in approximately 70% of breast cancers \[[@B34]\]. *ESR1* may serve to develop a hormonal therapy for breast cancer, since *ESR1* gene mutating is related to acquired endocrine resistance in patients with ER-positive metastatic breast cancer \[[@B27]\]. In the present study, lower expression level of *ESR1* was associated with shorter survival time. Previous research reported that *EDNRB* was methylated in prostate adenocarcinoma \[[@B24]\]. The methylation of *EDNRB* gene promoter was associated with gastric cancer invasion \[[@B37]\]. In our study, we found that *ESR1* and *EDNRB* expression levels were lower in cervical cancer samples than in the normal samples. Aberrant methylation may contribute to these differences. The rate of *ESR1* and *EDNRB* mutation was 6 and 7% in cervical cancer. Therefore, we speculated that the mutation resulted in the aberrant methylation or down-regulation of *ESR1* and *EDNRB*. Our study implied that *ESR1* and *EDNRB* may serve as targets in the creation of anti-tumor drugs.

GSEA was conducted to identify the functions of the five genes involved in cervical cancer. CAMs were enriched in TCGA samples. CAMs participate in various BPs, like differentiation, growth and apoptosis, and facilitate cellular interaction and migration \[[@B9],[@B13],[@B14]\]. In highly aggressive tumors, CAMs might show decreased immunoexpression \[[@B16]\]. Cervical cancers and their precursor lesions demonstrated the absence or alteration in cellular adherence \[[@B39]\]. During the development of cervical lesions, CAMs expression is altered either in location (cytoplasmic or membrane localization) or in quantity. E-cadherin is a number of CAM family that is aberrantly expressed in cervical lesions and leads to the invasion and metastasis of this neoplasm \[[@B9]\]. Taken together, low expression of CAMs could facilitate the metastasis of cervical cancer.

In conclusion, we conducted integrated bioinformatic analysis to identify aberrantly methylated and differentially expressed oncogenes and TSGs in cervical cancer tissues, as well as the related pathways and functions. Ten genes validated with the TCGA database, including five DMGs (*ESR1, EPB41L3, EDNRB,ID4, PLAC*), might be used as biomarkers and therapeutic targets in the precise diagnosis and treatment of cervical cancer.

The limitations in our study are as follows. First, since our research is a data analysis, biological experiments are in urgent need to validate our results. Second, it is necessary to explore the molecular mechanism in detail. In the future, we will deepen our research with well-designed experiments (including PCR, Western blot, BSP and COBRA).
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